GlaxoSmithKline plans to produce vaccines in Turkey

Sabah – British pharmaceuticals company GlaxoSmithKline (GSK) has announced plans to produce vaccines in Turkey with local company IDOL.
The world’s largest maker of vaccines plans to produce five vaccines for illnesses including hepatitis and influenza, while employing 80 scientists and researchers in Turkey.
In a statement given to the Turkish daily Sabah, President and General Manager of GSK Vaccines, Christophe Weber said that Turkey’s reforms undertaken in the last decade has transformed the country’s healthcare services to the point that vaccines were more readily available in Turkey than many of the EU countries.
GSK and IDOL plans to produce 17 million doses of vaccines per year initially, increasing to 30 million doses in the near future. GSK runs its Middle Eastern and African operations, covering 30 countries,  IIT